Revenio Group Corporation: Transfer of the Company's own shares
Revenio Group Corporation, Stock Exchange Release, September 18, 2020 at 12.00
Transfer of the Company's own shares
Revenio Group Corporation has transferred on August 21, 2020 2,126 shares (REG1V) to the members of the Board of Directors as part of remuneration of the Board.
Revenio Group Corporation's AGM decided on June 8, 2020 that 40% of the fee paid to a board member should be paid in company shares while 60% will comprise a monetary payment. The AGM decided that the Chair of the Board be entitled to an annual emolument of EUR 48,000, the Board members who act as the Chairman of the Committee be entitled to an annual emolument of EUR 30,000 and the other Board members to an annual emolument of EUR 24,000. The share payment will be valued using the weighted average value of the share on the day following the release of the Interim Report January 1- June 30, 2020.
As a result of these transfers, the share-based board member fees have been completely settled for the year 2020. Revenio Group Corporation now holds a total of 131,058 of its own shares.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Jouni Toijala, CEO, tel. +358 50 484 0085
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Revenio Group in brief
Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure measurement devices under the Icare brand and retinal imaging devices. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group comprises, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment.
In 2019, the Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.